Targeted delivery of mesenchymal stem cells to the bone

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Osteoporosis is a disease of excess skeletal fragility that results from estrogen loss and aging. Age related bone loss has been attributed to both elevated bone resorption and insufficient bone formation. We developed a hybrid compound, LLP2A-Ale in which LLP2A has high affinity for the α4β1 integrin on mesenchymal stem cells (MSCs) and alendronate has high affinity for bone. When LLP2A-Ale was injected into mice, the compound directed MSCs to both trabecular and cortical bone surfaces and increased bone mass and bone strength. Additional studies are underway to further characterize this hybrid compound, LLP2A-Ale, and how it can be utilized for the treatment of bone loss resulting from hormone deficiency, aging, and inflammation and to augment bone fracture healing. This article is part of a Special Issue entitled "Stem Cells and Bone".

Original languageEnglish (US)
Pages (from-to)62-65
Number of pages4
JournalBone
Volume70
DOIs
StatePublished - Jan 1 2015

Fingerprint

Mesenchymal Stromal Cells
Bone and Bones
Osteoporosis
Alendronate
Fracture Healing
Bone Fractures
Bone Resorption
Osteogenesis
Integrins
Estrogens
Stem Cells
Hormones
Inflammation
LLP2A compound

Keywords

  • Bone mass
  • Bone strength
  • Mesenchymal stem cells
  • Osteoblasts
  • Osteoporosis

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Targeted delivery of mesenchymal stem cells to the bone. / Yao, Wei; Lane, Nancy E.

In: Bone, Vol. 70, 01.01.2015, p. 62-65.

Research output: Contribution to journalArticle

@article{7d402f97d311421c9e752dd27639d8a8,
title = "Targeted delivery of mesenchymal stem cells to the bone",
abstract = "Osteoporosis is a disease of excess skeletal fragility that results from estrogen loss and aging. Age related bone loss has been attributed to both elevated bone resorption and insufficient bone formation. We developed a hybrid compound, LLP2A-Ale in which LLP2A has high affinity for the α4β1 integrin on mesenchymal stem cells (MSCs) and alendronate has high affinity for bone. When LLP2A-Ale was injected into mice, the compound directed MSCs to both trabecular and cortical bone surfaces and increased bone mass and bone strength. Additional studies are underway to further characterize this hybrid compound, LLP2A-Ale, and how it can be utilized for the treatment of bone loss resulting from hormone deficiency, aging, and inflammation and to augment bone fracture healing. This article is part of a Special Issue entitled {"}Stem Cells and Bone{"}.",
keywords = "Bone mass, Bone strength, Mesenchymal stem cells, Osteoblasts, Osteoporosis",
author = "Wei Yao and Lane, {Nancy E}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.bone.2014.07.026",
language = "English (US)",
volume = "70",
pages = "62--65",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Targeted delivery of mesenchymal stem cells to the bone

AU - Yao, Wei

AU - Lane, Nancy E

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Osteoporosis is a disease of excess skeletal fragility that results from estrogen loss and aging. Age related bone loss has been attributed to both elevated bone resorption and insufficient bone formation. We developed a hybrid compound, LLP2A-Ale in which LLP2A has high affinity for the α4β1 integrin on mesenchymal stem cells (MSCs) and alendronate has high affinity for bone. When LLP2A-Ale was injected into mice, the compound directed MSCs to both trabecular and cortical bone surfaces and increased bone mass and bone strength. Additional studies are underway to further characterize this hybrid compound, LLP2A-Ale, and how it can be utilized for the treatment of bone loss resulting from hormone deficiency, aging, and inflammation and to augment bone fracture healing. This article is part of a Special Issue entitled "Stem Cells and Bone".

AB - Osteoporosis is a disease of excess skeletal fragility that results from estrogen loss and aging. Age related bone loss has been attributed to both elevated bone resorption and insufficient bone formation. We developed a hybrid compound, LLP2A-Ale in which LLP2A has high affinity for the α4β1 integrin on mesenchymal stem cells (MSCs) and alendronate has high affinity for bone. When LLP2A-Ale was injected into mice, the compound directed MSCs to both trabecular and cortical bone surfaces and increased bone mass and bone strength. Additional studies are underway to further characterize this hybrid compound, LLP2A-Ale, and how it can be utilized for the treatment of bone loss resulting from hormone deficiency, aging, and inflammation and to augment bone fracture healing. This article is part of a Special Issue entitled "Stem Cells and Bone".

KW - Bone mass

KW - Bone strength

KW - Mesenchymal stem cells

KW - Osteoblasts

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=84918552423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918552423&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2014.07.026

DO - 10.1016/j.bone.2014.07.026

M3 - Article

C2 - 25173607

AN - SCOPUS:84918552423

VL - 70

SP - 62

EP - 65

JO - Bone

JF - Bone

SN - 8756-3282

ER -